Abstract
Objective: Few studies have examined toxicity from potentially curative chemotherapy in ovarian cancer patients at risk for breast cancer susceptibility (BRCA) mutation. Methods/Results: Ninety-four of the 482 patients appeared at risk for a mutation based on family history and 23 had a confirmed mutation. Hospitalization or emergency department visits were not increased based on family history with odds ratios (95% confidence intervals) of 0.88 (0.52, 1.45) (p =.62) and 0.90 (0.49, 1.58) (p =.71), respectively; similar findings were observed with confirmed mutations. Trends favored improved survival. Conclusions: Concern for a BRCA mutation should not preclude full dose chemotherapy in ovarian cancer patients treated with curative intent.
Original language | English (US) |
---|---|
Pages (from-to) | 531-535 |
Number of pages | 5 |
Journal | Cancer Investigation |
Volume | 34 |
Issue number | 10 |
DOIs | |
State | Published - Nov 25 2016 |
Keywords
- Ovarian cancer
- chemotherapy
- treatment
ASJC Scopus subject areas
- Oncology
- Cancer Research